[go: up one dir, main page]

ATE196315T1 - Interleukin-15 - Google Patents

Interleukin-15

Info

Publication number
ATE196315T1
ATE196315T1 AT94915781T AT94915781T ATE196315T1 AT E196315 T1 ATE196315 T1 AT E196315T1 AT 94915781 T AT94915781 T AT 94915781T AT 94915781 T AT94915781 T AT 94915781T AT E196315 T1 ATE196315 T1 AT E196315T1
Authority
AT
Austria
Prior art keywords
polypeptides
derivatives
interleukin
mammalian
etf
Prior art date
Application number
AT94915781T
Other languages
English (en)
Inventor
Kenneth H Grabstein
Dirk M Anderson
June R Eisenman
Charles Rauch
Victor Fung
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Priority claimed from ZA942636A external-priority patent/ZA942636B/xx
Application granted granted Critical
Publication of ATE196315T1 publication Critical patent/ATE196315T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT94915781T 1994-04-06 1994-04-06 Interleukin-15 ATE196315T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US1994/003793 WO1995027722A1 (en) 1994-04-06 1994-04-06 Interleukin-15
NZ266264A NZ266264A (en) 1994-04-06 1994-04-06 Mammalian epithelium-derived t-cell factor called interleukin-15
ZA942636A ZA942636B (en) 1994-04-06 1994-04-18 Interleukin-15
OA60897A OA10375A (en) 1994-04-06 1996-09-27 Interleukin-15

Publications (1)

Publication Number Publication Date
ATE196315T1 true ATE196315T1 (de) 2000-09-15

Family

ID=33314371

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94915781T ATE196315T1 (de) 1994-04-06 1994-04-06 Interleukin-15

Country Status (11)

Country Link
EP (1) EP0772624B1 (de)
AT (1) ATE196315T1 (de)
CA (1) CA2186747C (de)
DE (1) DE69425906T2 (de)
DK (1) DK0772624T3 (de)
ES (1) ES2151927T3 (de)
GR (1) GR3035019T3 (de)
NZ (1) NZ266264A (de)
OA (1) OA10375A (de)
PT (1) PT772624E (de)
WO (1) WO1995027722A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE221784T1 (de) * 1995-04-02 2002-08-15 Chugai Pharmaceutical Co Ltd Arzneimittel zur heilung von thrombozytopenie
CA2231603C (en) 1995-10-17 2009-04-21 Wayne State University Chicken interleukin-15 and uses thereof
US6509313B1 (en) 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
ES2243995T3 (es) * 1996-04-26 2005-12-01 Beth Israel Deaconess Medical Center, Inc. Antagonistas de interleucina-15.
US6451308B1 (en) 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
DK0927254T3 (da) * 1996-04-26 2005-10-03 Beth Israel Hospital Interleukin-15-antagonister
US6087172A (en) * 1997-10-31 2000-07-11 Hisamitsu Pharmaceutical Co., Inc. Ribozymes targeted to human IL-15 mRNA
US5985663A (en) * 1998-11-25 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of interleukin-15 expression
US6828147B1 (en) 1999-02-24 2004-12-07 The Wistar Institute Of Anatomy And Biology Method of modifying cytotoxic cells and uses thereof
EP1155115A4 (de) * 1999-02-24 2002-03-27 Wistar Inst Methode zur modifizierung zytotoxischer zellen und deren verwendungen
CA2408691A1 (en) 2000-05-12 2001-11-22 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
CU23093A1 (es) * 2002-10-09 2005-10-19 Ct Ingenieria Genetica Biotech Composición vacunal que comprende interleucina-15 (il-15)
CN100427597C (zh) * 2003-11-26 2008-10-22 中国医学科学院基础医学研究所 可用于生产人重组白细胞介素-15的原核表达工程菌及纯化方法
CU23472A1 (es) 2004-09-17 2009-12-17 Ct Ingenieria Genetica Biotech Péptido antagonista de la interleucina-15
ATE549398T1 (de) * 2004-10-08 2012-03-15 Us Gov Health & Human Serv Adoptive immuntherapie mit erhöhter t-lymphozyten-lebensdauer
PT1899364T (pt) 2005-05-17 2020-05-20 Univ Connecticut Composições e métodos para imunomodulação num organismo
EP1777294A1 (de) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi Domäin als selektieve und potente Enhancer von IL-15 Aktion durch IL-15Rbeta/gamma, und Hyperagonist (IL15Ralpha sushi -IL15) Fusionsproteine
JP5709356B2 (ja) 2006-01-13 2015-04-30 アメリカ合衆国 哺乳動物細胞における発現のためのコドン最適化ＩＬ−１５およびＩＬ−１５Ｒ−α遺伝子
ES2642008T3 (es) 2007-05-11 2017-11-14 Altor Bioscience Corporation Moléculas de fusión y variantes de IL-15
NZ703668A (en) 2007-06-27 2016-07-29 Us Sec Dep Of Health And Human Services Complexes of il-15 and il-15ralpha and uses thereof
WO2009135031A1 (en) 2008-04-30 2009-11-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Substituted il-15
ES2598005T3 (es) 2009-08-14 2017-01-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Uso de IL-15 para aumentar la salida del timo y para tratar la linfopenia
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
PT2619229T (pt) 2010-09-21 2016-07-13 Altor Bioscience Corp Moléculas de fusão de il-15 multiméricas solúveis e métodos de produção e utilização das mesmas
EP2537933A1 (de) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Auf IL-15- und IL-15Ralpha-Sushi-Domäne basierende Immunozytokine
CN104769104A (zh) 2011-12-12 2015-07-08 细胞药物有限公司 扩大t细胞的方法
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
ES2928851T3 (es) 2012-02-09 2022-11-23 Baylor College Medicine Mezclas pep para generar CTL multivíricos con amplia especificidad
HUE058364T2 (hu) 2013-04-19 2022-07-28 Cytune Pharma Citokinbõl származó kezelés redukált vaszkuláris permeabilitási szindrómával
EP2915569A1 (de) 2014-03-03 2015-09-09 Cytune Pharma Reinigungsverfahren für Il-15/Il-15Ralpha-basierte Konjugate
MA39711A (fr) 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
KR102503476B1 (ko) 2014-06-30 2023-02-24 알토 바이오사이언스 코포레이션 Il-15-베이즈드 분자 및 이의 사용 방법
IL298359A (en) 2015-09-18 2023-01-01 Baylor College Medicine Immunogenic detection of antigen from a pathogen and adjustment of effective clinical treatment
EP3468581A1 (de) 2016-06-13 2019-04-17 Torque Therapeutics, Inc. Verfahren und zusammensetzungen zur förderung der immunzellenfunktionen
BR112019007920A2 (pt) 2016-10-21 2019-10-08 Altor Bioscience Corp moléculas multiméricas à base de il-15
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
EP4317422A3 (de) 2017-04-13 2024-05-01 Senti Biosciences, Inc. Kombinatorische krebsimmuntherapie
IL270634B1 (en) 2017-05-15 2025-02-01 Nektar Therapeutics Long-acting interleukin-15 receptor agonists and related immunotherapeutic agents and methods
KR102008429B1 (ko) 2017-06-30 2019-08-07 아주대학교산학협력단 인터루킨-15/인터루킨-15 수용체 알파-Fc 복합체를 포함하는 염증질환 치료 또는 예방용 조성물
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス， インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US10993967B2 (en) 2018-10-17 2021-05-04 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
JP2023553419A (ja) 2020-12-03 2023-12-21 センチュリー セラピューティクス，インコーポレイテッド 遺伝子操作細胞およびその使用
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CN116981685A (zh) * 2020-12-03 2023-10-31 世纪治疗股份有限公司 基因工程化细胞及其用途
WO2023086772A1 (en) 2021-11-12 2023-05-19 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b

Also Published As

Publication number Publication date
DE69425906T2 (de) 2001-03-29
DE69425906D1 (en) 2000-10-19
ES2151927T3 (es) 2001-01-16
EP0772624A1 (de) 1997-05-14
EP0772624B1 (de) 2000-09-13
CA2186747A1 (en) 1995-10-19
GR3035019T3 (en) 2001-03-30
DK0772624T3 (da) 2000-11-13
WO1995027722A1 (en) 1995-10-19
OA10375A (en) 2001-11-16
CA2186747C (en) 2009-01-27
NZ266264A (en) 1997-01-29
PT772624E (pt) 2001-03-30
EP0772624A4 (de) 1997-07-02

Similar Documents

Publication Publication Date Title
ATE196315T1 (de) Interleukin-15
NO975437L (no) Nytt CD40L-mutein
MX9800719A (es) Proteinas de transporte y sus usos.
DK0669929T3 (da) Elk-ligand, et cytokin
DE69725587D1 (de) Verwendung von wnt polypeptiden
DE69334111D1 (en) Cd27 ligand
ATE335078T1 (de) Überexpression von säugetier- und virusproteinen
DE69738586D1 (de) Hohe expressionsrate von proteinen
MX9503362A (es) Nuevos anticuerpos br96 mutantes y equivalentes funcionales que reaccionan con carcinomas humanos.
BG100974A (en) Vaccines against papillomavirus
NO854460L (no) Syntetisk hepatitis-b-vaksine inbefattende baade t-celle og b-celledeterminanter.
MX9708426A (es) Polipeptido hk2 de variante estable.
AU4401689A (en) Recombinant dna coding for bacillus thuringiensis endotoxin
DE59410132D1 (de) Humanes zirkulierendes cytokin cc-1
EP0785716A4 (de) Als lerk6 bezeichnetes cytokin
GB9826143D0 (en) Tumour rejection antigens
AU656353B2 (en) New variants derived from interferons of type I, production process thereof and their applications
SE9401380D0 (sv) Ny celltillväxt-relaterad peptid och användning därav
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
NO974713D0 (no) Gener som koder for lymfocyttinterferon-regulatorisk faktor (LSIRF) polypeptider
AU637589B2 (en) Ancrod proteins, their production and use
EP0248642A3 (en) Interleukin-2 induced antineoplastic peptide
DE59009060D1 (de) Überexpression von Proteinen in rekombinanten Wirtszellen.
AU1305097A (en) Protein induced by deprenyl$m(3)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification